CD274 and neoplasm: As single agents, immunotherapies targeting the PD-1/PD-L1 signaling axis have demonstrated unprecedented capabilities to elicit anti-tumor immune responses in some patients with advanced cancers (21–23), however the fact remains; there are a large percentage of non-responders or initial responders that acquire resistance (29, 68).